Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.

This is a Phase I/II interventional, open-label treatment study designed to evaluate the safety and efficacy of concomitant therapy with anti-CD19 CAR T-cells and Lenalidomide in adult patients with relapsed/refractory chronic lymphocytic leukemia (CLL) who have been pretreated with Ibrutinib for 3 months prior to leukapheresis.

Trial Details

NCT ID
NCT06762431
Phase
PHASE1 / PHASE2
Sponsor
Vitebsk Regional Clinical Cancer Centre
Status
RECRUITING
Cancer Type
T-Cell Lymphoma Lymphoma
Interventions
  • Lenalidomide
  • Obinutuzumab Injection [Gazyva]
Locations (sample)
  • Vitebsk, Select A State, Belarus|55.1904,30.2049

Key Eligibility Criteria

  • Documented CD19+ CLL or SLL
  • Patients must have failed at least 1 prior regimen
  • Patients must be currently receiving ibrutinib for at least 3 months prior to enrollment in the study and:
  • Not experiencing any ≥ grade 2 non-hematologic ibrutinib-related toxicity

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find T-Cell Lymphoma Lymphoma Trials on Trialify →